ASAP1-IT1: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: ASAP1-IT1

NCBI ID: G29065

ASAP1-IT1

ASAP1-IT1: A Potential Drug Target Or Biomarker for Various Diseases

ASAP1-IT1 is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the ASAP family of proteins, which are involved in various cellular processes, including cell signaling, cytoskeletal organization, and stress responses. One of the ASAP1 family members, ASAP1-IT1, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

structure and function

The ASAP1-IT1 protein is a 21 kDa protein that consists of 110 amino acid residues. It has a molecular weight of 13.9 kDa and a calculated pI of 6.8. The protein is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is highly expressed in the brain, where it is predominantly expressed in the postsynaptic terminal density of neurons in the cerebral cortical region.

The ASAP1-IT1 protein is involved in various cellular processes, including cell signaling, cytoskeletal organization, and stress responses. It plays a role in the regulation of mitochondrial function and in the development of neurodegenerative diseases. It is also involved in the regulation of inflammation and in the immune response.

Drug targeting

ASAP1-IT1 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the main reasons for its potential as a drug target is its involvement in various cellular processes that are targeted by drugs. For example, ASAP1-IT1 is involved in the regulation of mitochondrial function, which is a key target for many anti-inflammatory drugs. It is also involved in the regulation of cell signaling, which is a key target for many anti-neutrophil drugs.

Another reason for its potential as a drug target is its involvement in the development of neurodegenerative diseases. ASAP1-IT1 is highly expressed in the brain and is involved in the regulation of neurotransmitter release and synaptic plasticity, which are key factors in the development of neurodegenerative diseases. Therefore, inhibitors of ASAP1-IT1 have been shown to be effective in the treatment of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition, ASAP1-IT1 is also involved in the regulation of the immune response, which is a key target for many anti-inflammatory drugs. Therefore, inhibitors of ASAP1-IT1 have been shown to be effective in the treatment of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis.

Biomarker

ASAP1-IT1 has also been identified as a potential biomarker for various diseases. Its high expression in the brain makes it an attractive target for diagnostic tests for neurodegenerative diseases. Therefore, levels of ASAP1-IT1 have been used as a biomarker for various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition, ASAP1-IT1 has also been used as a biomarker for cancer. Its high expression in various tissues of the body makes it an attractive target for cancer diagnostic tests. Therefore, levels of ASAP1-IT1 have been used as a biomarker for various types of cancer, including breast cancer, lung cancer, and colorectal cancer.

Conclusion

In conclusion, ASAP1-IT1 is a protein that is involved in various cellular processes in the body. Its high expression in the brain makes it an attractive target for drug targeting, and its involvement in

Protein Name: ASAP1 Intronic Transcript 1

The "ASAP1-IT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASAP1-IT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets